Thursday, 15 October 2026European Markets

BOIRON Stock Over 27% Up In The Last 21 Sessions

Loading stream...

boiron sa (cac 40: boi.pa), one of the world's premier homeopathy companies, experienced an astounding 27.69% jump over 21 sessions to close at eur50.50 on monday - offsetting any decrease of 0.29% experienced by france's primary market index cac 40. this introduction to the company's recent performance sets a promising tone to their market standing.

share performance and investor trust

boiron's shares have seen an impressive rebound recently but remain 5.64% below their 52-week high of eur53.20, suggesting there may be additional room for growth. on the other hand, they have already significantly outshone their 52-week low of eur37.00 which speaks volumes about investor trust in its resilience amid changing market trends.

financial key metrics

boiron boasts a trailing twelve month earnings per share (eps) of eur2.89 and trades with a price-to-earnings ratio (per) of 17.47; this indicates investors are willing to pay eur17.47 per euro of boiron's annual earnings. meanwhile, their return on equity (roe) stands at 8.13% indicating profit generation relative to net income equity.

revenue and share price volatility

boiron saw revenue grow 4.6% year-on-year to reach 534.24m over the last twelve months, yet its share price remains volatile; an intraday variation rate for last week recorded at negative 0.20%.

dividend and yield estimates

according to morningstar's estimates, boiron will pay its next dividend on june 1st 2023 at an expected forward annual dividend rate of 1.1% with an expected yield of 2.2% - providing investors with both income and growth potential.

product diversity and market potential

boiron's efforts across its product lines range from homeopathic remedies for treating flu symptoms to treatments for skin irritations. as global health concerns continue to dominate the healthcare market, boiron may benefit from in-vitro diagnostics, dietary supplements, and phytotherapy as a means to stay on an upward trend despite stock market fluctuations; investors seem to recognize boiron's diversity offerings as promising assets with which they may profit.

more news about boiron (boi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com